Results 31 to 40 of about 379,288 (191)

The effects of acute administration of losartan, angiotensin II type-1 receptor antagonist, on hemodynamics and oxidative stress parameters in malignant hypertensive rats [PDF]

open access: yesVeterinarski Glasnik, 2015
Malignant hypertension is a severe form of hypertension which pathogenesis is not fully elucidated. The aim of our study was to investigate the role of Angiotensin II on hemodynamic and oxidative stress parameters in model of malignant ...
Bogunović Natalija   +7 more
doaj   +1 more source

Bilateral disk edema with retinitis pigmentosa: Diagnostic dilemma

open access: yesIndian Journal of Ophthalmology. Case Reports, 2023
Bilateral disk edema in a case of retinitis pigmentosa can cause diagnostic confusion and delay in treatment. Existing literature shows few such cases where inflammatory pathology is postulated.
Priyadarshini Mishra   +3 more
doaj   +1 more source

A case report of malignant hypertension in a young woman [PDF]

open access: yes, 2016
Malignant hypertension is a condition characterized by severe hypertension and multi-organ ischemic complications. Albeit mortality and renal survival have improved with antihypertensive therapy, progression to end-stage renal disease remains a ...
BERNARDI, STELLA   +7 more
core   +1 more source

A Case of Malignant Hypertension-Induced Thrombotic Microangiopathy with Gradually Improved Renal Function Using Appropriate Antihypertensives

open access: yesTurkish Journal of Nephrology, 2021
Malignant hypertension sometimes causes microangiopathic hemolytic anemia (MAHA) and thrombotic microangiopathy (TMA). TMA results in the obstruction of arterioles and capillaries due to microvascular thrombosis. The pathological diagnosis of TMA is done
Feyza Bora   +3 more
doaj   +1 more source

Human leukocyte antigens and malignant essential hypertension

open access: yes, 1998
The purpose of this study was to investigate an association between human leukocyte antigens (HLA) and the susceptibility to malignant hypertension. the presence of HLA-A -B, -DR, and -DQ was determined in 33 white and in 23 mulatto Brazilian patients ...
Bernardes-Silva, H.   +9 more
core   +1 more source

Clinical characteristics and genetic profile of complement system in renal thrombotic microangiopathy in patients with severe forms of arterial hypertension

open access: yesТерапевтический архив
Background. The spectrum of diseases characterized by the development of renal thrombotic microangiopathy (TMA) encompasses the malignant hypertension (MHT).
Mariam I. Akaeva   +7 more
doaj   +1 more source

Malignant hypertension in atypical HUS

open access: yes, 2022
Introduction Atypical hemolytic uremic syndrome (aHUS) is a rare form of thrombotic microangiopathy (TMA) often caused by alternative complement dysregulation.
Vande Walle, Johan
core  

A case of malignant hypertension

open access: yesThe British Journal of Radiology, 1992
A 44-year-old woman presented with a 3 day history of central visual field impairment in the left eye, which had not changed since onset. The only past medical history of note was that during both pregnancies she had been hypertensive, for which she had required hospital admission.
P H, Williams, A P, Hemingway
openaire   +2 more sources

Bilateral and metastatic pheochromocytoma in a 11-year-old child: A case report

open access: yesJournal of Pediatric Surgery Case Reports, 2023
Introduction: Pheochromocytomas are rare neuroendocrine tumors. Bilateral and metastatic pheochromocytoma in children is even rarer. We report a case of a 11-year-old girl presenting with malignant hypertension related to a bilateral and metastatic ...
Takwa Mili   +7 more
doaj   +1 more source

Oxidative stress in malignant and non-malignant phase hypertension.

open access: yes, 2002
Malignant hypertension (MHT) is a rare and severe form of hypertension characterised by arteriolar necrosis and severe vascular damage, leading to stroke, myocardial infarction and death. We hypothesised that in addition to endothelial damage, MHT may be
Edmunds, E   +11 more
core   +1 more source

Home - About - Disclaimer - Privacy